Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

Calendar

07:00am - Ex-dividend date - 0.06 CNY

More about the company

Quotes

Date	Price	Change	Volume
29/06/26	CN¥12.85	-2.95%	21,777,900
26/06/26	CN¥13.24	-5.36%	12,592,200
25/06/26	CN¥13.99	-4.96%	14,323,300
24/06/26	CN¥14.72	-0.88%	13,854,000
23/06/26	CN¥14.85	-3.76%	17,286,900

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 29/06/2026			5-day change	1st Jan Change
12.85 ^CNY	-2.95%		-17.84%	+9.83%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	5.2B 766M 670M 618M 577M 1.09B 72.37B 1.11B 7.43B 2.87B 35.72B 2.87B 2.81B 124B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	5.55B 817M 715M 659M 616M 1.16B 77.23B 1.19B 7.93B 3.07B 38.12B 3.07B 3B 132B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.74%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-25	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-27	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 30, 2026	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
11/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
23/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI

1 day	-2.95%
1 week	-17.84%
Current month	-21.07%
1 month	-13.18%
3 months	+16.39%
6 months	+7.80%
Current year	+9.83%

GuiZhou SanLi Pharmaceutical Co.,Ltd Stock

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	12.1	15.6
1 month	12.1	17.46
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	27/05/2024
Hai Zhang CEO	Chief Executive Officer	41	01/09/2011
Ke Guo DFI	Director of Finance/CFO	39	01/11/2024

Director	Title	Age	Since
Hai Zhang CHM	Chairman	41	01/03/2018
Qian Fan Zhang BRD	Director/Board Member	41	01/03/2018
Yong Jian Sheng BRD	Director/Board Member	52	28/01/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
02/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
05/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-2.95%	-17.84%	+11.45%	-22.26%	788M
ELI LILLY AND COMPANY	+1.81%	+11.96%	+58.61%	+168.13%	1,077B
JOHNSON & JOHNSON	+1.51%	+13.19%	+69.61%	+58.63%	613B
ABBVIE INC.	+0.38%	+17.47%	+39.49%	+91.92%	448B
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+22.04%	332B
ASTRAZENECA PLC	-0.14%	+8.04%	+39.85%	+27.27%	293B
NOVARTIS AG	-0.06%	+6.68%	+31.21%	+42.55%	286B
NOVO NORDISK A/S	-0.96%	+7.49%	-28.02%	-40.86%	215B
AMGEN INC.	+0.62%	+6.80%	+30.10%	+62.92%	193B
GILEAD SCIENCES, INC.	-1.21%	+2.08%	+14.15%	+65.83%	159B
Average	-0.39%	+6.28%	+29.46%	+47.62%	361.69B
Weighted average by Cap.	+0.37%	+9.65%	+43.00%	+82.81%

	2024	2025
Net sales	2.14B 316M 276M 255M 238M 448M 29.84B 458M 3.06B 1.18B 14.73B 1.19B 1.16B 51.09B	1.7B 251M 219M 202M 189M 356M 23.7B 364M 2.43B 940M 11.7B 941M 921M 40.57B
Net income	274M 40.34M 35.31M 32.56M 30.42M 57.3M 3.81B 58.56M 392M 151M 1.88B 151M 148M 6.53B	46.25M 6.81M 5.96M 5.5M 5.13M 9.67M 644M 9.88M 66.1M 25.55M 318M 25.57M 25.01M 1.1B
Net Debt	108M 15.85M 13.87M 12.79M 11.95M 22.51M 1.5B 23.01M 154M 59.46M 740M 59.52M 58.21M 2.57B	349M 51.33M 44.93M 41.43M 38.71M 72.91M 4.85B 74.52M 498M 193M 2.4B 193M 189M 8.31B